Skip to main content
padlock icon - secure page this page is secure

What's new in Guillain-Barré syndrome in 2007–2008?

Buy Article:

$52.00 + tax (Refund Policy)

Abstract

The years 2007 and early 2008 have been an exciting time for Guillain-Barré syndrome (GBS) research. Epidemiological studies have shown that the incidence of GBS remains stable at about 2/100,000 per year but that there have been changes in hospitalization use, likely due to the widespread availability of IVIg. Research into mechanisms has shown the importance of single amino acids in Campylobacter jejuni and the importance of ganglioside conformation. In a murine model of anti-ganglioside antibody-mediated neuropathy, Eculizumab was effective in reversing clinical disease and preventing pathology. This suggests trials of Eculizumab in GBS should be considered. Unfortunately, there are no new randomized controlled trials in GBS to report although the unmet need is great.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Campylobacter jejuni; Guillain-Barré syndrome; epidemiology; ganglioside

Document Type: Research Article

Publication date: June 1, 2009

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more